MedTrace Logo

Stereotactic Body Proton Therapy for Treatment of Primary Renal Cell Carcinoma

NCT06376669 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-04-03

No results posted yet for this study

Summary

This study examines the impact of proton based stereotactic radiation therapy (SBRT) on kidney function as well as other oncologic outcomes including local control, locoregional and systemic failure, progression free and overall survival.

Conditions

Interventions

RADIATION

Proton Stereotactic Body Radiation therapy (SBRT)

Radiation therapy will consist of 3-5 treatments over 1.5 - 2 weeks

Sponsors & Collaborators

  • Robert L. Sloan Fund for Cancer Research

    collaborator OTHER

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    lead OTHER

Principal Investigators

  • Sherif Shaaban, MD · Johns Hopkins University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-25
Primary Completion
2027-06-30
Completion
2030-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06376669 on ClinicalTrials.gov